Evidence map›Paper›PMID 41311378›Full record

ArticleActa pharmaceutica Sinica. B2025

Engineered

Yuhong Wang, Lin Hu, Lei Wang, Chonghai Zhang, Wenhao Shen, Hongli Yang, Min Li, Xin Zhang, Mengmeng Xu, Muxing Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuhong WangDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Lin HuState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
Lei WangInstitute of Biology and Medical Sciences, Soochow University, Suzhou 215123, China.
Chonghai ZhangState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
Wenhao ShenState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
Hongli YangDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Min LiInstitute of Biology and Medical Sciences, Soochow University, Suzhou 215123, China.
Xin ZhangNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Mengmeng XuDepartment of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Muxing ZhangDepartment of Clinical Nutrition, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Kai YangDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Xiaopeng TianNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is an autoimmune disorder involving complex immune regulation, where balancing localized and systemic immunosuppression is a key challenge. This study aimed to enhance the therapeutic efficacy by engineering the probiotic

Indexed as

Escherichia coli Nissle 1917Gut microbesInflammatory bowel diseaseOuter membrane vesiclesProgrammed cell death ligand 1Protein deliveryTargeted local therapyT cell

Identifiers

PMID41311378
PMCPMC12647996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.